<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00414609</url>
  </required_header>
  <id_info>
    <org_study_id>CSPP100A2340</org_study_id>
    <nct_id>NCT00414609</nct_id>
    <nct_alias>NCT00699075</nct_alias>
  </id_info>
  <brief_title>Safety and Efficacy of Aliskiren in Post Myocardial Infarction Patients (ASPIRE)</brief_title>
  <official_title>A 36-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Including a 2 Year Extension Study to Evaluate Efficacy and Safety of Aliskiren on the Prevention of Left Ventricular Remodeling in High Risk Post-acute Myocardial Infarction Patients When Added to Optimized Standard Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The core and extension studies assessed the safety and efficacy of aliskiren when added to
      optimized standard therapy in patients that have had a high risk acute myocardial infarction
      (heart attack).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Core Study: Change From Baseline in Left Ventricular End Systolic Volume (LVESV) as Measured by Echocardiography at End of Study.</measure>
    <time_frame>Baseline and final visit (after 26 to 36 weeks of treatment)</time_frame>
    <description>Change from baseline to end of study in left ventricular end systolic volume (LVESV) as measured by echocardiography. LVESV is a measurement of the volume of blood in the heart's left ventricular chamber at the end of the heart's contraction. This measurement was made by the echocardiography lab. LVESV values between 22 to 58 mL for men and 19-49 mL for women are considered normal. Baseline LVESV was a covariate.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Extension Study: Percentage of Participants With Deaths, Serious Adverse Events (SAEs), Discontinuation for Adverse Events (AEs) and Discontinuations for Abnormal Lab Values</measure>
    <time_frame>Extension study (24 weeks)</time_frame>
    <description>AEs are defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome or disease which either occurs during study, having been absent at baseline, or, if present at baseline, appears to worsen. Serious adverse events are any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgment of investigators represent significant hazards.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Core Study: Time to First Occurrence for the Composite Endpoints of Echocardiogram and Adjudicated Outcomes</measure>
    <time_frame>LVEF was measured at baseline and at final visit (after 26 to 36 weeks of treatment). Other endpoint components were assessed from randomization until the end of the study (week 36).</time_frame>
    <description>Composite outcome 1 included: Cardiovascular (CV) Death, hospitalization for heart failure (HF), or absolute reduction in Left Ventricular Ejection Fraction (LVEF) greater than 6%. Composite outcome 2 included: CV Death, hospitalization for HF, recurrent Myocardial Infarction, Stroke, or Resuscitated Sudden Death. LVEF was measured at baseline and final visit. All other events were adjudicated by a blinded external committee. Each composite endpoint analysis was based on (a) the percent of patients with that endpoint and (b) days in study to 1st event (or last exposure if no event occurred).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Core Study: Change From Baseline in Left Ventricular End Diastolic Volume (LVEDV)</measure>
    <time_frame>Baseline and final visit (after 26 to 36 weeks of treatment)</time_frame>
    <description>Change from baseline to end of study in left ventricular end diastolic volume (LVEDV) as measured by echocardiography. (LVEDV) is a measurement of the volume of blood in the heart's left ventricular chamber at the beginning of the chamber's filling with blood. This measurement was made by the echocardiography lab. LVEDV values between 67 to 155 mL for men and 56 to 104 mL for women are considered normal. Baseline LVEDV was a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Core Study: Change From Baseline in Left Ventricular Ejection Fraction (LVEF)</measure>
    <time_frame>Baseline and final visit (after 26 to 36 weeks of treatment )</time_frame>
    <description>Change from baseline to end of study in left ventricular ejection fraction (LVEF) (%) as measured by echocardiography. LVEF is the fraction of blood (in percent) pumped out of the heart's left ventricular chamber with each heart beat, and is a measure of cardiac output for the heart. This measurement was made by the echocardiography lab. Ejection fraction percentages &gt; 55% are considered normal. Baseline LVEF was a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Core Study: Change From Baseline to End of Study in Infarction Segment Length (ISL) as Measured by Echocardiography</measure>
    <time_frame>Baseline and final visit (after 26 to 36 weeks of treatment)</time_frame>
    <description>Change from baseline to end of study in infarction segment length (ISL) (%) as measured by echocardiography. This is the length of the myocardial infarction segment as a percentage of the total cavity perimeter length as calculated by the echocardiography lab. Baseline ISL was a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Core Study: Change From Baseline to End of Study in Wall Motion Score (WMS) as Measured by Echocardiography</measure>
    <time_frame>Baseline and final visit (after 26 to 36 weeks of treatment)</time_frame>
    <description>Change from baseline to end of study in Wall Motion Score (WMS) as measured by echocardiography. WMS was obtained by examining multiple segments of the left ventricle and assigning each segment a score based on myocardial thickening: 1 for normal, 2 for hypokinetic; 3 for akinetic; and 4 for dyskinetic. The WMS was obtained as the average score for the segments visualized and was calculated by the echocardiography lab. Possible values range from 1 to 5. Higher scores are considered worse. Baseline WMS was a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extension Study: Change From Baseline in Left Ventricular End Systolic Volume (LVESV) at Month 12</measure>
    <time_frame>Baseline(extension study), Month 12 (extension study)</time_frame>
    <description>Change from baseline to Month 12 in left ventricular end systolic volume (LVESV) as measured by echocardiography. LVESV is a measurement of the volume of blood in the heart's left ventricular chamber at the end of the heart's contraction. This measurement was made by the echocardiography lab. LVESV values between 22 to 58 mL for men and 19-49 mL for women are considered normal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extension Study: Change From Baseline in Left Ventricular End Diastolic Volume (LVEDV) at Month 12</measure>
    <time_frame>Baseline (extension study), Month 12 (extension study)</time_frame>
    <description>Change from baseline to Month 12 in left ventricular end diastolic volume (LVEDV) as measured by echocardiography. LVEDV is a measurement of the volume of blood in the heart's left ventricular chamber at the beginning of the chamber's filling with blood. This measurement was made by the echocardiography lab. LVEDV values between 67 to 155 mL for men and 56 to 104 mL for women are considered normal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extension Study: Change From Baseline in Left Ventricular Ejection Fraction (LVEF) at Month 12</measure>
    <time_frame>Baseline(extension study), Month 12 (extension study)</time_frame>
    <description>Change from baseline to Month 12 in left ventricular ejection fraction (LVEF) (%) as measured by echocardiography. LVEF is the fraction of blood (in percent) pumped out of the heart's left ventricular chamber with each heart beat, and is a measure of cardiac output for the heart. This measurement was made by the echocardiography lab. Ejection fraction percentages &gt; 55% are considered normal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extension Study: Percentage of Participants With Orthostatic Blood Pressure Change</measure>
    <time_frame>Baseline (Day 0 Extension study), Week 2, Months 1, 3, 6, 9,16, 20, 24</time_frame>
    <description>Orthostatic blood pressure change is defined as a decrease of at least 20 mmHg in systolic blood pressure or a decrease of at least 10 mmHg in diastolic blood pressure when a patient moves from a sitting position to a standing position. A patient could show orthostatic blood pressure change at more than one visit. End of study is Month 24 or early discontinuation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extension Study: Percentage of Participants With Specified Criteria in Selected Labs by Laboratory Parameter</measure>
    <time_frame>24 Months</time_frame>
    <description>Fasting blood samples were collected throughout the study and were analyzed at a central laboratory. Percentage of participants with the following clinically significant laboratory values are reported:
Potassium &lt;3.5 mmol/L; Low value (Normal reference range: 3.5- 5.3)
Potassium &gt;5.5 mmol/L and Potassium &gt;6.0 mmol/L; High values (Normal reference range: 3.5-5.3)
Creatinine &gt;176.8 μmol/L; High value (Normal reference range= Male: 62- 106 and Female 44- 80)
Blood Urea Nitrogen (BUN) &gt;14.28; High value (Normal reference range: 2.1- 8.9)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">820</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Aliskiren</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Core Study: Aliskiren ascending doses: 75 mg tablet for 1st week, 150 mg for 2nd week, 300 mg for next 34 weeks orally once daily in the morning.
Extension Study: Patients from both the core arms who completed core study and signed informed consent form were included in this arm of extension study.
Patients received 150 mg aliskiren tablet orally once a day for two weeks. Patients were then up-titrated to 300 mg aliskiren orally once a day at the discretion of the principal investigator based on their clinical condition for the duration of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Core study: placebo for 36 weeks once daily in the morning</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aliskiren</intervention_name>
    <description>Aliskiren was available in 75 mg tablet, 150 mg tablet</description>
    <arm_group_label>Aliskiren</arm_group_label>
    <other_name>Tekturna®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo tablets matching aliskiren for 36 weeks once daily in the morning for core period only.</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Core Study Inclusion Criteria:

          -  Male or female patients 18 years and older.

          -  Patients within 7-42 days of an acute myocardial infarction associated with left
             ventricular systolic dysfunction.

          -  Documented left ventricular systolic dysfunction associated with the qualifying acute
             myocardial.

          -  Patients must be on stable doses of the following concomitant medications for at least
             2 weeks prior to Visit 1 unless contraindicated due to intolerance:

               -  A Beta-blocker

               -  An Anti-platelet agent

               -  A Statin

               -  An evidence-based dose of an Angiotensin Converting Enzyme Inhibitor (ACEI) or
                  Angiotensin Receptor Blocker (ARB) but not both.

          -  Qualifying Echocardiogram at Visit 1:

        Core Study Exclusion Criteria:

          -  Patients requiring both Angiotensin Converting Enzyme Inhibitor (ACEI) and Angiotensin
             Receptor Blocker (ARB) combination therapy at V1 or any time during the study.

          -  Severe refractory hypertension defined as mean sitting systolic blood pressure (MSSBP)
             ≥ 180 mmHg and/or mean sitting diastolic blood pressure (MSDBP) ≥ 110 mmHg) at Visit
             2.

          -  Cardiogenic shock or systolic BP &lt; 100 mmHg or diastolic &lt; 60 mmHg within the 24 hours
             prior to Visits 1 or 2

          -  Estimated Glomerular Filtration Rate (eGFR) &lt; 30 ml/min/1.73m2 using the MDRD formula
             at Visit 1.

          -  Stroke or transient ischemic event (TIA) within 6 months of Study Visit 1

        Extension Study Inclusion Criteria:

          -  Male or female patients who completed the core study through Visit 10 while on
             double-blind study drug

          -  Patients who were able to participate in the study, and who consented to do so after
             the purpose and nature of the study had been clearly explained to them (written
             informed consent)

        Extension Study Exclusion Criteria:

          -  New York Heart Association (NYHA) class IV Congestive Heart Failure at Visit 1 (Core
             study Visit 10)

          -  Symptomatic hypotension or reported systolic blood pressure (BP) &lt; 90 mmHg within 24
             hours prior to Visit 1 (Core study Visit 10)

          -  Known Estimated Glomerular Filtration Rate (eGFR) &lt; 30 mL/min/1.73m^2 using the
             Modification of Diet in Renal Disease (MDRD) formula at Visit 1 (Core study Visit 10)

          -  Pregnant or nursing (lactating) women, where pregnancy was defined as the state of a
             female after conception and until the termination of gestation, confirmed by a
             positive hCG laboratory test (&gt; 5 mIU/mL)

          -  Women of child-bearing potential, defined as all women physiologically capable of
             becoming pregnant Unless post-menopausal or using an acceptable method of
             contraception

          -  Any surgical or medical condition that in the opinion of the investigator may place
             the patient at higher risk from his/her participation in the study or was likely to
             prevent the patient from complying with the requirements or completing the study

        Other protocol-defined inclusion/exclusion criteria applied
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis US</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis US</name>
      <address>
        <city>Novartis US</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Argentina</name>
      <address>
        <city>Novartis Argentina</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Belgium</name>
      <address>
        <city>Novartis Belgium</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Canada</name>
      <address>
        <city>Novartis Canada</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis de Colombia S.A.</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Czech Republic</name>
      <address>
        <city>Praha</city>
        <state>Praha 3</state>
        <zip>CZ-130 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Denmark</name>
      <address>
        <city>Novartis Denmark</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Germany</name>
      <address>
        <city>Novartis Germany</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Hungary</name>
      <address>
        <city>Budapest</city>
        <zip>H-1537</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Healthcare Private Limited</name>
      <address>
        <city>Worli, Mumbai</city>
        <zip>400018</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Pharma</name>
      <address>
        <city>Petach Tikva</city>
        <zip>IL-49250</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Italy</name>
      <address>
        <city>Novartis Italy</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Korea Ltd.</name>
      <address>
        <city>Seoul</city>
        <zip>100-803</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Netherlands</name>
      <address>
        <city>Novartis Netherlands</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Norway</name>
      <address>
        <city>Novartis Norway</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Poland Sp. z o.o.</name>
      <address>
        <city>Warszawa</city>
        <zip>PL-00-710-</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Russia</name>
      <address>
        <city>Novartis Russia</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Slovakia</name>
      <address>
        <city>Bratislava</city>
        <zip>SK-821 09</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Spain</name>
      <address>
        <city>Novartis Spain</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Sweden</name>
      <address>
        <city>Novartis Sweden</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Turkey</name>
      <address>
        <city>Istanbul</city>
        <zip>TR-34353</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis UK</name>
      <address>
        <city>Novartis</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis de Venezuela, S.A.</name>
      <address>
        <city>Caracas</city>
        <zip>1062</zip>
        <country>Venezuela</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Colombia</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
    <country>Venezuela</country>
  </location_countries>
  <removed_countries>
    <country>Brazil</country>
    <country>Peru</country>
  </removed_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2006</study_first_submitted>
  <study_first_submitted_qc>December 20, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2006</study_first_posted>
  <results_first_submitted>December 20, 2010</results_first_submitted>
  <results_first_submitted_qc>June 14, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 13, 2011</results_first_posted>
  <last_update_submitted>July 5, 2012</last_update_submitted>
  <last_update_submitted_qc>July 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>myocardial infarction, aliskiren, heart failure</keyword>
  <keyword>Post acute myocardial infarction with systolic dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo_Core</title>
          <description>Placebo for 36 weeks once daily in the morning</description>
        </group>
        <group group_id="P2">
          <title>Aliskiren_Core</title>
          <description>Aliskiren ascending doses: 75 mg tablet for 1st week, 150 mg for 2nd week, 300 mg for the next 34 weeks orally once daily in the morning.</description>
        </group>
        <group group_id="P3">
          <title>Aliskiren_Extension</title>
          <description>Patients from both the arms of the core study who completed core study and signed informed consent form were included in this arm of extension study.
Patients received 150 mg aliskiren tablet orally once a day for two weeks. Patients were then up-titrated to 300 mg aliskiren orally once a day at the discretion of the principal investigator based on their clinical condition for the duration of the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Core Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="397"/>
                <participants group_id="P2" count="423"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="397"/>
                <participants group_id="P2" count="422"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Echocardiogram Evaluable Set</title>
              <participants_list>
                <participants group_id="P1" count="330"/>
                <participants group_id="P2" count="343"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="363"/>
                <participants group_id="P2" count="378"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="45"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal laboratory values</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal test procedure results</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol deviation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient withdrew consent</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative problems</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Extension Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="422">Patients of both core arms who completed core study and signed informed consent form for extension.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Echocardiogram (ECHO) Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="400"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="365"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="57"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unsatisfactory therapeutic effect</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative problems</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo for 36 weeks once daily in the morning</description>
        </group>
        <group group_id="B2">
          <title>Aliskiren</title>
          <description>Aliskiren ascending doses: 75 mg tablet for 1st week, 150 mg for 2nd week, 300 mg for the next 34 weeks orally once daily in the morning.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="397"/>
            <count group_id="B2" value="423"/>
            <count group_id="B3" value="820"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Demographics were measured for core randomized population</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.4" spread="11.67"/>
                    <measurement group_id="B2" value="60.7" spread="11.63"/>
                    <measurement group_id="B3" value="60.0" spread="11.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="261"/>
                    <measurement group_id="B2" value="254"/>
                    <measurement group_id="B3" value="515"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 65 years and &lt; 75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                    <measurement group_id="B2" value="114"/>
                    <measurement group_id="B3" value="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="336"/>
                    <measurement group_id="B2" value="343"/>
                    <measurement group_id="B3" value="679"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Core Study: Change From Baseline in Left Ventricular End Systolic Volume (LVESV) as Measured by Echocardiography at End of Study.</title>
        <description>Change from baseline to end of study in left ventricular end systolic volume (LVESV) as measured by echocardiography. LVESV is a measurement of the volume of blood in the heart’s left ventricular chamber at the end of the heart’s contraction. This measurement was made by the echocardiography lab. LVESV values between 22 to 58 mL for men and 19-49 mL for women are considered normal. Baseline LVESV was a covariate.</description>
        <time_frame>Baseline and final visit (after 26 to 36 weeks of treatment)</time_frame>
        <population>Echocardiogram evaluable set (patients who had acceptable echocardiogram measurements both at baseline and at post-baseline after receiving at least 26 weeks of treatment)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo_Core</title>
            <description>Placebo for 36 weeks once daily in the morning</description>
          </group>
          <group group_id="O2">
            <title>Aliskiren_Core</title>
            <description>Aliskiren ascending doses: 75 mg tablet for 1st week, 150 mg for 2nd week, 300 mg for the next 34 weeks orally once daily in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Core Study: Change From Baseline in Left Ventricular End Systolic Volume (LVESV) as Measured by Echocardiography at End of Study.</title>
          <description>Change from baseline to end of study in left ventricular end systolic volume (LVESV) as measured by echocardiography. LVESV is a measurement of the volume of blood in the heart’s left ventricular chamber at the end of the heart’s contraction. This measurement was made by the echocardiography lab. LVESV values between 22 to 58 mL for men and 19-49 mL for women are considered normal. Baseline LVESV was a covariate.</description>
          <population>Echocardiogram evaluable set (patients who had acceptable echocardiogram measurements both at baseline and at post-baseline after receiving at least 26 weeks of treatment)</population>
          <units>mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="329"/>
                <count group_id="O2" value="343"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.14" spread="1.01"/>
                    <measurement group_id="O2" value="-4.13" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Core Study: Time to First Occurrence for the Composite Endpoints of Echocardiogram and Adjudicated Outcomes</title>
        <description>Composite outcome 1 included: Cardiovascular (CV) Death, hospitalization for heart failure (HF), or absolute reduction in Left Ventricular Ejection Fraction (LVEF) greater than 6%. Composite outcome 2 included: CV Death, hospitalization for HF, recurrent Myocardial Infarction, Stroke, or Resuscitated Sudden Death. LVEF was measured at baseline and final visit. All other events were adjudicated by a blinded external committee. Each composite endpoint analysis was based on (a) the percent of patients with that endpoint and (b) days in study to 1st event (or last exposure if no event occurred).</description>
        <time_frame>LVEF was measured at baseline and at final visit (after 26 to 36 weeks of treatment). Other endpoint components were assessed from randomization until the end of the study (week 36).</time_frame>
        <population>Full Analysis Set (FAS) – All randomized patients who either (a) received study drug or (b) did not receive study drug but were not disqualified from randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo_Core</title>
            <description>Placebo for 36 weeks once daily in the morning</description>
          </group>
          <group group_id="O2">
            <title>Aliskiren_Core</title>
            <description>Aliskiren ascending doses: 75 mg tablet for 1st week, 150 mg for 2nd week, 300 mg for the next 34 weeks orally once daily in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Core Study: Time to First Occurrence for the Composite Endpoints of Echocardiogram and Adjudicated Outcomes</title>
          <description>Composite outcome 1 included: Cardiovascular (CV) Death, hospitalization for heart failure (HF), or absolute reduction in Left Ventricular Ejection Fraction (LVEF) greater than 6%. Composite outcome 2 included: CV Death, hospitalization for HF, recurrent Myocardial Infarction, Stroke, or Resuscitated Sudden Death. LVEF was measured at baseline and final visit. All other events were adjudicated by a blinded external committee. Each composite endpoint analysis was based on (a) the percent of patients with that endpoint and (b) days in study to 1st event (or last exposure if no event occurred).</description>
          <population>Full Analysis Set (FAS) – All randomized patients who either (a) received study drug or (b) did not receive study drug but were not disqualified from randomization.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="397"/>
                <count group_id="O2" value="423"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Composite Outcome 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0"/>
                    <measurement group_id="O2" value="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Composite Outcome 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6"/>
                    <measurement group_id="O2" value="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Core Study: Change From Baseline in Left Ventricular End Diastolic Volume (LVEDV)</title>
        <description>Change from baseline to end of study in left ventricular end diastolic volume (LVEDV) as measured by echocardiography. (LVEDV) is a measurement of the volume of blood in the heart’s left ventricular chamber at the beginning of the chamber’s filling with blood. This measurement was made by the echocardiography lab. LVEDV values between 67 to 155 mL for men and 56 to 104 mL for women are considered normal. Baseline LVEDV was a covariate.</description>
        <time_frame>Baseline and final visit (after 26 to 36 weeks of treatment)</time_frame>
        <population>Echocardiogram evaluable set: Patients who had acceptable echocardiogram measurements both at baseline and at post-baseline after receiving at least 26 weeks of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo_Core</title>
            <description>Placebo for 36 weeks once daily in the morning</description>
          </group>
          <group group_id="O2">
            <title>Aliskiren_Core</title>
            <description>Aliskiren ascending doses: 75 mg tablet for 1st week, 150 mg for 2nd week, 300 mg for the next 34 weeks orally once daily in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Core Study: Change From Baseline in Left Ventricular End Diastolic Volume (LVEDV)</title>
          <description>Change from baseline to end of study in left ventricular end diastolic volume (LVEDV) as measured by echocardiography. (LVEDV) is a measurement of the volume of blood in the heart’s left ventricular chamber at the beginning of the chamber’s filling with blood. This measurement was made by the echocardiography lab. LVEDV values between 67 to 155 mL for men and 56 to 104 mL for women are considered normal. Baseline LVEDV was a covariate.</description>
          <population>Echocardiogram evaluable set: Patients who had acceptable echocardiogram measurements both at baseline and at post-baseline after receiving at least 26 weeks of treatment.</population>
          <units>mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="329"/>
                <count group_id="O2" value="343"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.37" spread="1.19"/>
                    <measurement group_id="O2" value="-3.08" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Core Study: Change From Baseline in Left Ventricular Ejection Fraction (LVEF)</title>
        <description>Change from baseline to end of study in left ventricular ejection fraction (LVEF) (%) as measured by echocardiography. LVEF is the fraction of blood (in percent) pumped out of the heart’s left ventricular chamber with each heart beat, and is a measure of cardiac output for the heart. This measurement was made by the echocardiography lab. Ejection fraction percentages &gt; 55% are considered normal. Baseline LVEF was a covariate.</description>
        <time_frame>Baseline and final visit (after 26 to 36 weeks of treatment )</time_frame>
        <population>Echocardiogram evaluable set: Patients who had acceptable echocardiogram measurements both at baseline and at post-baseline after receiving at least 26 weeks of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo_Core</title>
            <description>Placebo for 36 weeks once daily in the morning</description>
          </group>
          <group group_id="O2">
            <title>Aliskiren_Core</title>
            <description>Aliskiren ascending doses: 75 mg tablet for 1st week, 150 mg for 2nd week, 300 mg for the next 34 weeks orally once daily in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Core Study: Change From Baseline in Left Ventricular Ejection Fraction (LVEF)</title>
          <description>Change from baseline to end of study in left ventricular ejection fraction (LVEF) (%) as measured by echocardiography. LVEF is the fraction of blood (in percent) pumped out of the heart’s left ventricular chamber with each heart beat, and is a measure of cardiac output for the heart. This measurement was made by the echocardiography lab. Ejection fraction percentages &gt; 55% are considered normal. Baseline LVEF was a covariate.</description>
          <population>Echocardiogram evaluable set: Patients who had acceptable echocardiogram measurements both at baseline and at post-baseline after receiving at least 26 weeks of treatment.</population>
          <units>percent of blood pumped from LV chamber</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="329"/>
                <count group_id="O2" value="343"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.12" spread="0.27"/>
                    <measurement group_id="O2" value="2.24" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Core Study: Change From Baseline to End of Study in Infarction Segment Length (ISL) as Measured by Echocardiography</title>
        <description>Change from baseline to end of study in infarction segment length (ISL) (%) as measured by echocardiography. This is the length of the myocardial infarction segment as a percentage of the total cavity perimeter length as calculated by the echocardiography lab. Baseline ISL was a covariate.</description>
        <time_frame>Baseline and final visit (after 26 to 36 weeks of treatment)</time_frame>
        <population>Echocardiogram evaluable set: Patients who had acceptable echocardiogram measurements both at baseline and at post-baseline after receiving at least 26 weeks of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo_Core</title>
            <description>Placebo for 36 weeks once daily in the morning</description>
          </group>
          <group group_id="O2">
            <title>Aliskiren_Core</title>
            <description>Aliskiren ascending doses: 75 mg tablet for 1st week, 150 mg for 2nd week, 300 mg for the next 34 weeks orally once daily in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Core Study: Change From Baseline to End of Study in Infarction Segment Length (ISL) as Measured by Echocardiography</title>
          <description>Change from baseline to end of study in infarction segment length (ISL) (%) as measured by echocardiography. This is the length of the myocardial infarction segment as a percentage of the total cavity perimeter length as calculated by the echocardiography lab. Baseline ISL was a covariate.</description>
          <population>Echocardiogram evaluable set: Patients who had acceptable echocardiogram measurements both at baseline and at post-baseline after receiving at least 26 weeks of treatment.</population>
          <units>percent of total cavity perimeter length</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="330"/>
                <count group_id="O2" value="343"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.30" spread="0.53"/>
                    <measurement group_id="O2" value="-5.04" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Core Study: Change From Baseline to End of Study in Wall Motion Score (WMS) as Measured by Echocardiography</title>
        <description>Change from baseline to end of study in Wall Motion Score (WMS) as measured by echocardiography. WMS was obtained by examining multiple segments of the left ventricle and assigning each segment a score based on myocardial thickening: 1 for normal, 2 for hypokinetic; 3 for akinetic; and 4 for dyskinetic. The WMS was obtained as the average score for the segments visualized and was calculated by the echocardiography lab. Possible values range from 1 to 5. Higher scores are considered worse. Baseline WMS was a covariate.</description>
        <time_frame>Baseline and final visit (after 26 to 36 weeks of treatment)</time_frame>
        <population>Echocardiogram evaluable set: Patients who had acceptable echocardiogram measurements both at baseline and at post-baseline after receiving at least 26 weeks of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo_Core</title>
            <description>Placebo for 36 weeks once daily in the morning</description>
          </group>
          <group group_id="O2">
            <title>Aliskiren_Core</title>
            <description>Aliskiren ascending doses: 75 mg tablet for 1st week, 150 mg for 2nd week, 300 mg for the next 34 weeks orally once daily in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Core Study: Change From Baseline to End of Study in Wall Motion Score (WMS) as Measured by Echocardiography</title>
          <description>Change from baseline to end of study in Wall Motion Score (WMS) as measured by echocardiography. WMS was obtained by examining multiple segments of the left ventricle and assigning each segment a score based on myocardial thickening: 1 for normal, 2 for hypokinetic; 3 for akinetic; and 4 for dyskinetic. The WMS was obtained as the average score for the segments visualized and was calculated by the echocardiography lab. Possible values range from 1 to 5. Higher scores are considered worse. Baseline WMS was a covariate.</description>
          <population>Echocardiogram evaluable set: Patients who had acceptable echocardiogram measurements both at baseline and at post-baseline after receiving at least 26 weeks of treatment.</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="327"/>
                <count group_id="O2" value="340"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" spread="0.01"/>
                    <measurement group_id="O2" value="-0.10" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Extension Study: Percentage of Participants With Deaths, Serious Adverse Events (SAEs), Discontinuation for Adverse Events (AEs) and Discontinuations for Abnormal Lab Values</title>
        <description>AEs are defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome or disease which either occurs during study, having been absent at baseline, or, if present at baseline, appears to worsen. Serious adverse events are any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgment of investigators represent significant hazards.</description>
        <time_frame>Extension study (24 weeks)</time_frame>
        <population>Extension Population (considered as Safety population) consisting of all enrolled patients who received at least one dose of study medication in the extension study.</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren_Extension</title>
            <description>Patients from both the arms of the core study who completed core study and signed informed consent form were included in this arm of extension study.
Patients received 150 mg aliskiren tablet orally once a day for two weeks. Patients were then up-titrated to 300 mg aliskiren orally once a day at the discretion of the principal investigator based on their clinical condition for the duration of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Extension Study: Percentage of Participants With Deaths, Serious Adverse Events (SAEs), Discontinuation for Adverse Events (AEs) and Discontinuations for Abnormal Lab Values</title>
          <description>AEs are defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome or disease which either occurs during study, having been absent at baseline, or, if present at baseline, appears to worsen. Serious adverse events are any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgment of investigators represent significant hazards.</description>
          <population>Extension Population (considered as Safety population) consisting of all enrolled patients who received at least one dose of study medication in the extension study.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="422"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AE discontinuations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug-related AE discontinuations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAE discontinuations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinuations for abnormal lab values</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Extension Study: Change From Baseline in Left Ventricular End Systolic Volume (LVESV) at Month 12</title>
        <description>Change from baseline to Month 12 in left ventricular end systolic volume (LVESV) as measured by echocardiography. LVESV is a measurement of the volume of blood in the heart’s left ventricular chamber at the end of the heart’s contraction. This measurement was made by the echocardiography lab. LVESV values between 22 to 58 mL for men and 19-49 mL for women are considered normal.</description>
        <time_frame>Baseline(extension study), Month 12 (extension study)</time_frame>
        <population>Echocardiogram Analysis Set consisting of all patients in the extension population who had acceptable ECHO measurements at extension baseline and Month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren_Extension</title>
            <description>Patients from both the arms of the core study who completed core study and signed informed consent form were included in this arm of extension study.
Patients received 150 mg aliskiren tablet orally once a day for two weeks. Patients were then up-titrated to 300 mg aliskiren orally once a day at the discretion of the principal investigator based on their clinical condition for the duration of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Extension Study: Change From Baseline in Left Ventricular End Systolic Volume (LVESV) at Month 12</title>
          <description>Change from baseline to Month 12 in left ventricular end systolic volume (LVESV) as measured by echocardiography. LVESV is a measurement of the volume of blood in the heart’s left ventricular chamber at the end of the heart’s contraction. This measurement was made by the echocardiography lab. LVESV values between 22 to 58 mL for men and 19-49 mL for women are considered normal.</description>
          <population>Echocardiogram Analysis Set consisting of all patients in the extension population who had acceptable ECHO measurements at extension baseline and Month 12.</population>
          <units>Milliliter (mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.2" spread="14.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Extension Study: Change From Baseline in Left Ventricular End Diastolic Volume (LVEDV) at Month 12</title>
        <description>Change from baseline to Month 12 in left ventricular end diastolic volume (LVEDV) as measured by echocardiography. LVEDV is a measurement of the volume of blood in the heart’s left ventricular chamber at the beginning of the chamber’s filling with blood. This measurement was made by the echocardiography lab. LVEDV values between 67 to 155 mL for men and 56 to 104 mL for women are considered normal.</description>
        <time_frame>Baseline (extension study), Month 12 (extension study)</time_frame>
        <population>Echocardiogram Analysis Set consisting of all patients in the extension population who had acceptable ECHO measurements at extension baseline and Month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren_Extension</title>
            <description>150 mg aliskiren tablet orally once a day for two weeks. Patients were then up-titrated to 300 mg aliskiren orally once a day at the discretion of the principal investigator based on their clinical condition for the duration of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Extension Study: Change From Baseline in Left Ventricular End Diastolic Volume (LVEDV) at Month 12</title>
          <description>Change from baseline to Month 12 in left ventricular end diastolic volume (LVEDV) as measured by echocardiography. LVEDV is a measurement of the volume of blood in the heart’s left ventricular chamber at the beginning of the chamber’s filling with blood. This measurement was made by the echocardiography lab. LVEDV values between 67 to 155 mL for men and 56 to 104 mL for women are considered normal.</description>
          <population>Echocardiogram Analysis Set consisting of all patients in the extension population who had acceptable ECHO measurements at extension baseline and Month 12.</population>
          <units>Milliliter (mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" spread="18.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Extension Study: Change From Baseline in Left Ventricular Ejection Fraction (LVEF) at Month 12</title>
        <description>Change from baseline to Month 12 in left ventricular ejection fraction (LVEF) (%) as measured by echocardiography. LVEF is the fraction of blood (in percent) pumped out of the heart’s left ventricular chamber with each heart beat, and is a measure of cardiac output for the heart. This measurement was made by the echocardiography lab. Ejection fraction percentages &gt; 55% are considered normal.</description>
        <time_frame>Baseline(extension study), Month 12 (extension study)</time_frame>
        <population>Echocardiogram Analysis Set consisting of all patients in the extension population who had acceptable ECHO measurements at extension baseline and Month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren_Extension</title>
            <description>Patients from both the arms of the core study who completed core study and signed informed consent form were included in this arm of extension study.
Patients received 150 mg aliskiren tablet orally once a day for two weeks. Patients were then up-titrated to 300 mg aliskiren orally once a day at the discretion of the principal investigator based on their clinical condition for the duration of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Extension Study: Change From Baseline in Left Ventricular Ejection Fraction (LVEF) at Month 12</title>
          <description>Change from baseline to Month 12 in left ventricular ejection fraction (LVEF) (%) as measured by echocardiography. LVEF is the fraction of blood (in percent) pumped out of the heart’s left ventricular chamber with each heart beat, and is a measure of cardiac output for the heart. This measurement was made by the echocardiography lab. Ejection fraction percentages &gt; 55% are considered normal.</description>
          <population>Echocardiogram Analysis Set consisting of all patients in the extension population who had acceptable ECHO measurements at extension baseline and Month 12.</population>
          <units>percent of blood pumped from LV chamber</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4" spread="6.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Extension Study: Percentage of Participants With Orthostatic Blood Pressure Change</title>
        <description>Orthostatic blood pressure change is defined as a decrease of at least 20 mmHg in systolic blood pressure or a decrease of at least 10 mmHg in diastolic blood pressure when a patient moves from a sitting position to a standing position. A patient could show orthostatic blood pressure change at more than one visit. End of study is Month 24 or early discontinuation.</description>
        <time_frame>Baseline (Day 0 Extension study), Week 2, Months 1, 3, 6, 9,16, 20, 24</time_frame>
        <population>Extension population (considered as Safety population) consisted of all enrolled patients who received at least one dose of study medication in the extension study. &quot;n&quot; in each of the categories is the number of participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren_Extension</title>
            <description>Patients from both the arms of the core study who completed core study and signed informed consent form were included in this arm of extension study.
Patients received 150 mg aliskiren tablet orally once a day for two weeks. Patients were then up-titrated to 300 mg aliskiren orally once a day at the discretion of the principal investigator based on their clinical condition for the duration of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Extension Study: Percentage of Participants With Orthostatic Blood Pressure Change</title>
          <description>Orthostatic blood pressure change is defined as a decrease of at least 20 mmHg in systolic blood pressure or a decrease of at least 10 mmHg in diastolic blood pressure when a patient moves from a sitting position to a standing position. A patient could show orthostatic blood pressure change at more than one visit. End of study is Month 24 or early discontinuation.</description>
          <population>Extension population (considered as Safety population) consisted of all enrolled patients who received at least one dose of study medication in the extension study. &quot;n&quot; in each of the categories is the number of participants with data available at the given time-point.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="422"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=420)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n=416)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1 (n=418)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (n=410)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n=400)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9 (n=397)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=385)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 16 (n=383)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 20 (n=350)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 (n=360)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Study (n=422)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any post-baseline visit (n=422)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Extension Study: Percentage of Participants With Specified Criteria in Selected Labs by Laboratory Parameter</title>
        <description>Fasting blood samples were collected throughout the study and were analyzed at a central laboratory. Percentage of participants with the following clinically significant laboratory values are reported:
Potassium &lt;3.5 mmol/L; Low value (Normal reference range: 3.5- 5.3)
Potassium &gt;5.5 mmol/L and Potassium &gt;6.0 mmol/L; High values (Normal reference range: 3.5-5.3)
Creatinine &gt;176.8 μmol/L; High value (Normal reference range= Male: 62- 106 and Female 44- 80)
Blood Urea Nitrogen (BUN) &gt;14.28; High value (Normal reference range: 2.1- 8.9)</description>
        <time_frame>24 Months</time_frame>
        <population>Extension population (considered as Safety population) consisted of all enrolled patients who received at least one dose of study medication in the extension study. &quot;n&quot; in each of the categories is the number of participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren_Extension</title>
            <description>Patients from both the arms of the core study who completed core study and signed informed consent form were included in this arm of extension study.
Patients received 150 mg aliskiren tablet orally once a day for two weeks. Patients were then up-titrated to 300 mg aliskiren orally once a day at the discretion of the principal investigator based on their clinical condition for the duration of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Extension Study: Percentage of Participants With Specified Criteria in Selected Labs by Laboratory Parameter</title>
          <description>Fasting blood samples were collected throughout the study and were analyzed at a central laboratory. Percentage of participants with the following clinically significant laboratory values are reported:
Potassium &lt;3.5 mmol/L; Low value (Normal reference range: 3.5- 5.3)
Potassium &gt;5.5 mmol/L and Potassium &gt;6.0 mmol/L; High values (Normal reference range: 3.5-5.3)
Creatinine &gt;176.8 μmol/L; High value (Normal reference range= Male: 62- 106 and Female 44- 80)
Blood Urea Nitrogen (BUN) &gt;14.28; High value (Normal reference range: 2.1- 8.9)</description>
          <population>Extension population (considered as Safety population) consisted of all enrolled patients who received at least one dose of study medication in the extension study. &quot;n&quot; in each of the categories is the number of participants with data available at the given time-point.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="422"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Potassium &lt;3.5 mmol/L (n=409)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium &gt;5.5 mmol/L (n=409)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium ≥6.0 mmol/L (n=409)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine &gt;176.8 μmol/L (n=412)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BUN &gt;14.28 mmol/L (n=412)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Core Safety population: All patients that received at least one dose of study drug.
Extension Safety Population: All enrolled patients who received at least one dose of study medication in the extension study.
Extension study enrolled patients from both the arms of core who complete core study and signed an informed consent form.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo_core</title>
          <description>Placebo for 36 weeks once daily in the morning</description>
        </group>
        <group group_id="E2">
          <title>Aliskiren_core</title>
          <description>Aliskiren ascending doses: 75 mg tablet for 1st week, 150 mg for 2nd week, 300 mg for the next 34 weeks orally once daily in the morning.</description>
        </group>
        <group group_id="E3">
          <title>Aliskiren_extension</title>
          <description>Patients from both the arms of the core study who completed core study and signed informed consent form were included in this arm of extension study.
Patients received 150 mg aliskiren tablet orally once a day for two weeks. Patients were then up-titrated to 300 mg aliskiren orally once a day at the discretion of the principal investigator based on their clinical condition for the duration of the study.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="92" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="107" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="126" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Arteriospasm coronary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Coronary artery insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Abdominal tenderness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Chronic gastrointestinal bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Gastrointestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Inguinal hernia, obstructive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Mouth haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Apparent death</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Device failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Thrombosis in device</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Vessel puncture site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Enterococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Febrile infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Gastroenteritis norovirus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Peritoneal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Scrotal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Coronary artery restenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Face injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Graft thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Implantable defibrillator malfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>In-stent coronary artery restenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Medical device complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Thrombosis in device</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Blood pressure decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Ejection fraction decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QRS complex prolonged</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Renal function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Venous pressure jugular increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Hypophagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Fibromyalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Gouty arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Bile duct cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Brain cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Brain neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Carcinoid tumour of the pancreas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Metastatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Myeloproliferative disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Plasmacytoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Basilar artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Brain stem infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Cerebral microangiopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Encephalomalacia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Intercostal neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Parkinsonism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Nephropathy toxic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Hydrothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Hypercapnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Hyperventilation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Wegener's granulomatosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cold sweat</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hospitalisation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Angiopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Femoral artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="118" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="161" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="123" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="422"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

